Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C25H32N2O6 |
Molecular Weight | 456.5314 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12N3CC[C@@]14C5=C(C=C(OC)C=C5)N(C)[C@@]4([H])[C@](O)([C@H](OC(C)=O)[C@]2(CC)C=CC3)C(=O)OC
InChI
InChIKey=CXBGOBGJHGGWIE-ACSXSLCXSA-N
InChI=1S/C25H32N2O6/c1-6-23-10-7-12-27-13-11-24(19(23)27)17-9-8-16(31-4)14-18(17)26(3)20(24)25(30,22(29)32-5)21(23)33-15(2)28/h7-10,14,19-21,30H,6,11-13H2,1-5H3/t19-,20+,21+,23+,24+,25-/m0/s1
Molecular Formula | C25H32N2O6 |
Molecular Weight | 456.5314 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 5 / 6 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/24012527
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24012527
Vindoline (VDL) is an indole alkaloid, possessing hypoglycemic and vasodilator effects, and it is also the prodrug of many vinca alkaloids. Vindoline as one of the alkaloids is highly present in
young leaves and twigs of Catharanthus roseus, and oral administration of vindoline (100 mg/kg) had an acute hypoglycemic effect on rats. Vindoline acted as a Kv2.1 inhibitor able to reduce the voltage-dependent outward potassium currents finally enhancing insulin secretion. It protected β-cells from the cytokines-induced apoptosis following its inhibitory role in Kv2.1. Moreover, vindoline (20mg/kg) treatment significantly improved glucose homeostasis in db/db mice and STZ/HFD-induced type 2 diabetic rats, as reflected by its functions in increasing plasma insulin concentration, protecting the pancreatic β-cells from damage, decreasing fasting blood glucose and glycated hemoglobin (HbA1c), improving OGTT and reducing plasma triglyceride (TG).
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0030073 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24012527 |
50.0 µM [EC50] | ||
Target ID: CHEMBL1075226 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24012527 |
43.0 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Natural product vindoline stimulates insulin secretion and efficiently ameliorates glucose homeostasis in diabetic murine models. | 2013 Oct 28 |
|
Completion of the seven-step pathway from tabersonine to the anticancer drug precursor vindoline and its assembly in yeast. | 2015 May 12 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24012527
Daily oral treatment with vindoline (20mg/kg) to diabetic mice/rats for 4 weeks, body weight and blood glucose were determined every week, oral glucose tolerance test (OGTT) was performed after 4 weeks.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24012527
Vindoline dose-dependently
inhibited the sustained outward K+ current by IC50 of 31 uM in MIN6 cells, preincubated with nifedipine (10 uM). Vindoline efficiently reduced K+ current by IC50 of 43 uM in Kv2.1 over-expressing CHO cells. MIN6 cells were pretreated with vindoline (20 or 50 uM for 4 h), followed by incubation with apoptotic cytokines or vindoline (20 or 50 uM for another 24 h). The percentage of
the apoptotic MIN6 cells represented by FITC-AnnexinV was 9.41%
under normal condition, and the percentage became 26.36% with
treatment of apoptotic cytokines for 24 h, while vindoline (50 uM)
decreased the percentage of apoptotic cells by 16.45% in vindolinetreated
MIN6 cells.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:45:46 GMT 2023
by
admin
on
Fri Dec 15 15:45:46 GMT 2023
|
Record UNII |
571PJ1LW03
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1744
Created by
admin on Fri Dec 15 15:45:46 GMT 2023 , Edited by admin on Fri Dec 15 15:45:46 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID901045589
Created by
admin on Fri Dec 15 15:45:46 GMT 2023 , Edited by admin on Fri Dec 15 15:45:46 GMT 2023
|
PRIMARY | |||
|
57753
Created by
admin on Fri Dec 15 15:45:46 GMT 2023 , Edited by admin on Fri Dec 15 15:45:46 GMT 2023
|
PRIMARY | |||
|
2182-14-1
Created by
admin on Fri Dec 15 15:45:46 GMT 2023 , Edited by admin on Fri Dec 15 15:45:46 GMT 2023
|
PRIMARY | |||
|
628056
Created by
admin on Fri Dec 15 15:45:46 GMT 2023 , Edited by admin on Fri Dec 15 15:45:46 GMT 2023
|
PRIMARY | |||
|
m11455
Created by
admin on Fri Dec 15 15:45:46 GMT 2023 , Edited by admin on Fri Dec 15 15:45:46 GMT 2023
|
PRIMARY | Merck Index | ||
|
260535
Created by
admin on Fri Dec 15 15:45:46 GMT 2023 , Edited by admin on Fri Dec 15 15:45:46 GMT 2023
|
PRIMARY | |||
|
91994
Created by
admin on Fri Dec 15 15:45:46 GMT 2023 , Edited by admin on Fri Dec 15 15:45:46 GMT 2023
|
PRIMARY | |||
|
571PJ1LW03
Created by
admin on Fri Dec 15 15:45:46 GMT 2023 , Edited by admin on Fri Dec 15 15:45:46 GMT 2023
|
PRIMARY | |||
|
C1273
Created by
admin on Fri Dec 15 15:45:46 GMT 2023 , Edited by admin on Fri Dec 15 15:45:46 GMT 2023
|
PRIMARY | |||
|
218-558-0
Created by
admin on Fri Dec 15 15:45:46 GMT 2023 , Edited by admin on Fri Dec 15 15:45:46 GMT 2023
|
PRIMARY | |||
|
Vindoline
Created by
admin on Fri Dec 15 15:45:46 GMT 2023 , Edited by admin on Fri Dec 15 15:45:46 GMT 2023
|
PRIMARY | |||
|
16380
Created by
admin on Fri Dec 15 15:45:46 GMT 2023 , Edited by admin on Fri Dec 15 15:45:46 GMT 2023
|
PRIMARY |